Table 1.

Demographics and clinical assessments of the SLE subjects.

	SLE w/lesions (n =23)	SLE w/o lesions (n = 19)	p value
Age (years)	41.5±11.7	34.0±12.3	0.051
Female Gender	91.3%	94.7%	0.66*
Age of Onset of SLE (years)	31.4±11.1	26.2±14.6	0.21
Disease Duration (years)	11.0±8.0	7.5±5.7	0.11
Prednisone (mg/day)	13.0±41.4	5.8±11.3	0.43
Hydroxychloroquine	47.8%	47.4%	0.99*
Cyclophosphamide	26.1%	36.8%	0.52*
Mycophenylate	17.4%	10.5%	0.67*
SLEDAI (U)	11.9±10.5	10.2±7.7	0.55
SLICC-ACR/DAI (U)	3.7±2.5	3.1±2.3	0.39
Neuro-SLEDAI (U)	4.5±6.7	2.1±4.5	0.17
Neuro-SLICC (U)	1.2±1.3	0.6±0.9	0.08
Antinuclear antibody titer ((d(diluti (inverse)	294±396	360±463	0.62
Anti-ds-DNA antibody Titer (dilutions)(inverse)	14.9±36.9	54.0±59.8	0.02
C3 (mg/dL))	104±36	100±30	0.70
C4 (mg/dL))	25±35	16±7	0.27
Erythrocyte Sedimentation Rate (mm/hr)(mm/hr)	29±34	20±14	0.24
C-reactive protein (mg/dL))	1.2±1.7	1.1±1.5	0.75
aPL IgG (IU)	10.7±10.5	18.2±27.1	0.26
aPL IgM (IU)	12.0±17.7	10.0±14.3	0.70
aPL IgA (IU)	6.5±12.8	6.4±11.9	0.99
Lupus-like Inhibitor	27.3%	42.1%	0.35*
Anti-ribosomal P antibody (dilutions)	1.5±3.0	10.8±32.4	0.24

Satterthwaite’s t-test was used except for binary data* where Fisher’s Exact test was used.